GERM — ETFMG Treatments Testing and Advancements ETF

GERM Fund Overview

GERM — ETFMG Treatments Testing and Advancements ETF is a US ETF managed by ETF Managers Trust, categorised as United States Multi-Cap / All-Cap Blend / Core Materials Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.

• Type: US ETF
• Manager: ETF Managers Trust
• Category: United States Multi-Cap / All-Cap Blend / Core Materials Equity
• Assets under management: $12.78M
• 1-year return: -13.8%
• Ticker: GERM
• SEC CIK: 0001467831
• SEC series ID: S000068972
• Share class ID: C000220417

GERM Investment Objective and Strategy

ETFMG Treatments Testing and Advancements ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by ETF Managers Trust.

Investment objective

The ETFMG Treatments, Testing and Advancements ETF (the Fund or the Treatments ETF) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index (the Index).

Principal investment strategy

The Fund uses a passive or indexing approach to try to achieve the Funds investment objective. Unlike many investment companies, the Fund does not try to beat the Index and does not seek temporary defensive positions when markets decline or appear overvalued. The Fund will use a replication strategy. A replication strategy is an indexing strategy that involves investing in the securities of the Index in approximately the same proportions as in the Index. However, the Fund may utilize a representative sampling strategy with respect to the Index when a replication strategy might be detrimental to shareholders, such as when there are practical difficulties or substantial costs involved in compiling a portfolio of equity securities to follow the Index, in instances in which a security in the Index becomes temporarily illiquid, unavailable or less liquid, or as a result of legal restrictions or limitations (such as tax diversification requirements) that apply to the Fund but not the Index.

The Fund rebalances its portfolio in accordance with its Index, and, therefore, any changes to the Indexs rebalance schedule will result in corresponding changes to the Funds rebalance schedule. The Fund invests at least 80% of its total assets, exclusive of collateral held from securities lending, in the component securities of the Index. The Fund may invest up to 20% of its total assets in securities that are not in the Funds Index to the extent that the Funds adviser believes such investments should help the Funds overall portfolio track the Index. The Fund may also invest in other investment companies that principally invest in the types of instruments allowed by the investment strategies of the Fund. The Fund may lend its portfolio securities to brokers, dealers, and other financial organizations.

These loans, if and when made, may not exceed 33 1/3% of the total asset value of the Fund (including the loan collateral). By lending its securities, the Fund may increase its income by receiving payments from the borrower. Prime Treatments, Testing and Advancements Index The Index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. Such companies are identified by Prime Indexes (the Index Provider), an independent index provider that is not affiliated with the Funds investment adviser, based on the rules of the Index. The Index is comprised of two groups of companies, as described below: Treatment Companies and Testing Companies.

Treatment Companies are companies that (i) have one or more vaccines or treatments for infectious diseases in pre-clinical research, in any phase of U.S. Food and Drug Administration clinical trials, or in a commercial stage and (ii) are classified by the North American Industry Classification System as either Pharmaceutical and Medicine Manufacturing or Research and Development in the Physical, Engineering, and Life Sciences. Testing Companies are companies that derive more than 50% of their revenue from the research, development, manufacturing, and provision of biological tests for patients. To qualify for inclusion in the Index, Treatments Companies and Testing Companies must have an operating company structure (as opposed to being a pass-through security). To be added to the Index, Treatments Companies and Testing Companies must have a minimum market capitalization of US$100 million and an average daily value traded over the prior three month period of $250,000.

Companies already included in the Index must have a minimum market capitalization of US$50 million. The Index has a quarterly review in each March, June, September, and December, at which times the Index is reconstituted and rebalanced by the Index Provider. The composition of the Index and the constituent weights are determined on the two Thursdays before the second Friday of each March, June, September, and December (or the next business day if this is a non-business day). Component changes are made after the market close on the third Friday of each March, June, September, and December (or the next business day if the third Friday is not a business day) and become effective at the market opening on the next trading day. The five largest constituents with a market capitalization under US$15 billion are each weighted at 6% (30% in the aggregate).

The remaining constituents with a market capitalization under US$15 billion are weighted bases on their market capitalization subject to a 4% limit per security. Constituents with a market capitalization of US$15 billion or more will be equally weighted with an aggregate weighting of 10%. The Index is developed and owned by Prime Indexes, and the Index is calculated and maintained by Solactive AG. The Index Provider is not affiliated with Solactive AG, the Fund, or the Funds investment adviser. As of January 10, 2023, the Index had 68 components. The Fund will concentrate its investments ( i.e. , hold more than 25% of its net assets) in a particular industry or group of related industries to approximately the same extent that the Index is concentrated. As of January 10, 2023, the Index was concentrated in the biotechnology industry.

The Fund rebalances its portfolio in accordance with its Index, and, therefore, any changes to the Indexs rebalance schedule will result in corresponding changes to the Funds rebalance schedule. Correlation : Correlation is the extent to which the values of different types of investments move in tandem with one another in response to changing economic and market conditions. An index is a theoretical financial calculation, while the Fund is an actual investment portfolio. The performance of the Fund and the Index may vary somewhat due to transaction costs, asset valuations, foreign currency valuations, market impact, corporate actions (such as mergers and spin-offs), legal restrictions or limitations, illiquid or unavailable securities, and timing variances. The Funds investment adviser expects that, over time, the correlation between the Funds performance and that of the Index, before fees and expenses, will exceed 95%.

A correlation percentage of 100% would indicate perfect correlation. If the Fund uses a replication strategy, it can be expected to have greater correlation to the Index than if it uses a representative sampling strategy.

GERM Holdings

Top 10 holdings of ETFMG Treatments Testing and Advancements ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.

View all GERM holdings

GERM Portfolio Allocation

Asset-class allocation of ETFMG Treatments Testing and Advancements ETF by percentage of net assets, from the latest SEC N-PORT filing.

GERM Performance

Total returns for GERM (as of 2026-10-01), from SEC filings.

GERM Risk Information

Risk metrics for GERM, derived from monthly returns in SEC filings.

• 1-year volatility (annualised): 23.8%

GERM Costs and Fees

GERM costs about $68 per $10,000 invested per year in fund expenses.

• Net expense ratio: 0.68%
• Gross expense ratio: 0.68%
• Portfolio turnover: 30%
• Brokerage commissions: 16.03 bps of average net assets (SEC N-CEN)

GERM Cashflows

Over the 12 months to 2023-12, ETFMG Treatments Testing and Advancements ETF had net inflows of $8.38M, from monthly SEC N-PORT filings.

GERM Debt Constituents

No individual debt constituents are reported in ETFMG Treatments Testing and Advancements ETF's latest SEC N-PORT filing.

GERM Prospectus and SEC Filings

Official ETFMG Treatments Testing and Advancements ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.

• Prospectus (485BPOS) — filed 2023-01-26
• Prospectus (485BPOS) — filed 2022-01-28
• Prospectus (485BPOS) — filed 2021-01-29
• Portfolio holdings (N-PORT) — filed 2024-02-28
• Portfolio holdings (N-PORT) — filed 2023-11-28
• Portfolio holdings (N-PORT) — filed 2023-08-25
• Annual census (N-CEN) — filed 2023-12-14
• Annual census (N-CEN) — filed 2022-12-15

Related Funds

Related funds tracked on ABC INVEST:

• ETFMG Prime Cyber Security ETF (HACK)
• ETFMG Prime Junior Silver Miners ETF (SILJ)
• ETFMG Prime Mobile Payments ETF (IPAY)
• ETFMG Alternative Harvest ETF (MJ)
• Etho Climate Leadership U.S. ETF (ETHO)

Data Sources

ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.